The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma.

Authors: Zachary Buchwald, David C. Qian, Jeffrey Switchenko, Melinda Lynne Yushak, David H. Lawson, Michael Lowe

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9601

Source: Full article

---

Abstract

TPS9601